Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease

Value in Health

Volumn 11, Issue 1, 2008, Pages 57-75

  Kimel, Miriam ^a   Leidy, Nancy K ^a   Mannix, Sally ^a   Dixon, Julia ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Anemia; Cancer; Chronic disease; Epoetin alfa; Health related quality of life; HIV; Kidney disease

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; CHRONIC KIDNEY DISEASE; CHRONIC PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEOPLASM; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 38549171251     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00215.x     Document Type: Article

References (77)

1. Isselbacher KJ, Fauci A, Kasper D, et al. Harrison's Principles of Internal Medicine (13th ed.). New York : McGraw-Hill, 1994.
2. AIDS InfoNet. Fact sheet number 552 - Anemia. The New Mexico AIDS InfoNet [Internet], 2006. Revised March 15, 2006. Available from: http://www. aidsinfonet.org/factsheet_detail.php?fsnumber=552. [Accessed May 2006].
3. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC). Anemia in kidney disease and dialysis, 2005. NIH Publication No. 05-4619. Available from: http://kidney.niddk.nih.gov/ kudiseases/pubs/anemia/index.htm. [Accessed May 2006].
4. Barroso J. A review of fatigue in people with HIV infection. J Assoc Nurses AIDS Care 1999 10 : 42 9.
5. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005 352 : 1011 23.
6. Groopman JE. Fatigue in cancer and HIV/AIDS. Oncology (Williston Park) 1998 12 : 335 44 discussion 336 45, 351.
7. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981 24 : 1308 15.
8. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997 34 (3 Suppl. 2 S4 12.
9. McCann K, Boore JR. Fatigue in persons with renal failure who require maintenance haemodialysis. J Adv Nurs 2000 32 : 1132 42.
10. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001 91 : 2214 21.
11. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003 107 : 223 5.
12. Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001 38 : 955 62.
13. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999 10 : 610 19.
14. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002 100 : 2303 20.
15. KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006 47 (5 Suppl. 3 S11 145.
16. Volberding PA, Levine AM, Dieterich D, et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis 2004 38 : 1454 63.
17. Krantz SB. Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 1994 307 : 353 9.
18. Physicians' Desk Reference. Montvale, NJ : Thomson Healthcare, 2005.
19. Itri LM. Managing cancer-related anaemia with epoetin alfa. Nephrol Dial Transplant 2002 17 (Suppl. 1 S73 7.
20. Breiterman-White R. Functional ability of patients on dialysis: the critical role of anemia. Nephrol Nurs J 2005 32 : 79 82.
21. Leonard RC, Untch M, Von Koch F. Management of anaemia in patients with breast cancer: role of epoetin. Ann Oncol 2005 16 : 817 24.
22. Wilson A, Yu HT, Goodnough LT, Nissenson AR. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 2004 116 (Suppl. 7) A : S50 7.
23. Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med 2004 116 (Suppl. 7) A : S27 43.
24. Aapro M, Bajetta E, Freund M, et al. Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy? Eur J Cancer 2004 2 (Suppl. 2 S20 8.
25. Bajetta E, Vercammen E, Reinhardt U, et al. Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy. Tumori 2004 90 : 449 57.
26. Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003 21 : 366 73.
27. Fairclough DL, Gagnon DD, Zagari MJ, et al. Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients. Qual Life Res 2003 12 : 1013 27.
28. Fallowfield L, Gagnon D, Zagari M, et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002 87 : 1341 53.
29. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001 19 : 2865 74.
30. Littlewood TJ, Nortier J, Rapoport B, et al. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol 2003 21 : 169 80.
31. Patrick DL, Gagnon DD, Zagari MJ, et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003 39 : 335 45.
32. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005 23 : 2606 17.
33. Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992 87 (Suppl. 1 S4 11.
34. Case DC Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993 85 : 801 6.
35. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001 113 : 172 9.
36. Granetto C, Ricci S, Martoni A, et al. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy. Oncol Rep 2003 10 : 1289 96.
37. Sweeney PJ, Nicolae D, Ignacio L, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998 77 : 1996 2002.
38. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004 104 : 321 7.
39. Chang J, Couture F, Young S, et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005 23 : 2597 605.
40. Iconomou G, Koutras A, Rigopoulos A, et al. Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial. J Pain Symptom Manage 2003 25 : 512 18.
41. O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 2005 5 : 439 46.
42. Savonije JH, van Groeningen CJ, van Bochove A, et al. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter randomised controlled trial. Eur J Cancer 2005 41 : 1560 9.
43. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997 34 (3 Suppl. 2 13 19.
44. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998 16 : 3412 15.
45. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997 13 : 63 74.
46. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001 19 : 2875 82.
47. Cella D, Eton DT, Lai JS, et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002 24 : 547 61.
48. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997 15 : 1218 34.
49. Gough IR, Furnival CM, Schilder L, Grove W. Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 1983 19 : 1161 5.
50. Bernhard J, Maibach R, Thurlimann B, et al. Patients' estimation of overall treatment burden: why not ask the obvious? J Clin Oncol 2002 20 : 65 72.
51. Sloan J. Asking the obvious questions regarding patient burden. J Clin Oncol 2002 20 : 4 6.
52. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003 41 : 582 92.
53. Grossman HA, Goon B, Bowers P, Leitz G. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients. J Acquir Immune Defic Syndr 2003 34 : 368 78.
54. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med 1992 117 : 739 48.
55. Sulkowski MS, Dieterich DT, Bini EJ, et al. Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr 2005 39 : 504 6.
56. Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. Int J STD AIDS 2000 11 : 659 65.
57. Revicki DA, Brown RE, Henry DH, et al. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. J Acquir Immune Defic Syndr 1994 7 : 474 84.
58. Saag MS, Bowers P, Leitz GJ, Levine AM. Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients. AIDS Res Hum Retroviruses 2004 20 : 1037 45.
59. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care 1991 29 : 786 98.
60. Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care 1998 36 : 126 37.
61. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997 6 : 481 93.
62. Chan KS, Revicki DA. Changes in surrogate laboratory markers, clinical endpoints, and health-related quality of life in patients infected with the human immunodeficiency virus. Eval Health Prof 1998 21 : 265 81.
63. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995 25 : 548 54.
64. The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991 18 : 50 9.
65. Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004 61 : 392 405.
66. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981 19 : 787 805.
67. Ware JE, Kosinski M, Gandek B. SF-36 Health Survey: Manual & Interpretation Guide. Lincoln, RI : QualityMetric Incorporated, 1993.
68. Moreno F, Aracil FJ, Perez R, Valderrabano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis 1996 27 : 548 56.
69. McMahon LP, Dawborn JK. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. Am J Nephrol 1992 12 : 162 9.
70. Laupacis A, Wong C, Churchill D. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group. Control Clin Trials 1991 12 (4 Suppl. S168 79.
71. Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute - CKD study. Am J Kidney Dis 2005 45 : 658 66.
72. Rebollo P, Baltar JM, Campistol JM, et al. Quality of life of patients with chronic renal allograft rejection and anemia. J Nephrol 2004 17 : 531 6.
73. Walters BA, Hays RD, Spritzer KL, et al. Health-related quality of life, depressive symptoms, anemia, and malnutrition at hemodialysis initiation. Am J Kidney Dis 2002 40 : 1185 94.
74. Beusterien KM, Nissenson AR, Port FK, et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 1996 7 : 763 73.
75. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004 15 : 979 86.
76. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002 20 : 2486 94.
77. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002 95 : 888 95.